GLP-1 Receptor Agonists in Civil Aircrew: Evidence, Regulatory Divergence, and a Proposal for Harmonized Certification
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including the dual agonist tirzepatide and the oral agents semaglutide and orforglipron, are increasingly prescribed for obesity, a condition common among airline pilots. Civil aviation authorities now accept these drugs in aircrew, but their guidance differs and has not been compared with the pharmacology of each agent. The evidence on the pharmacology, benefits, and adverse effects of GLP-1 RAs relevant to flight and on their interactions with the flight environment was reviewed. The guidance of civil aviation authorities in the United States, the United Kingdom, the European Union, New Zealand, Australia, and Canada was also compared. The half-life of the regulated agents ranges from two to three days for orforglipron to about one week for semaglutide, so that exposure approaches steady state between one and five weeks after each change in dose. Gastrointestinal adverse events are frequent and cluster during dose escalation, whereas acute kidney injury, pancreatitis, and gallbladder disease may also occur later in treatment. Signals for nonarteritic anterior ischemic optic neuropathy, increased heart rate, and vestibular symptoms carry low absolute risks but are relevant to flight duty. Benefits include fewer major adverse cardiovascular events (MACE) and less severe obstructive sleep apnea (OSA). Cabin altitude, low humidity, and circadian disruption may add to the gastrointestinal effects of these drugs, although no study has tested them in flight. Observation periods ranged from one to four weeks after initiation and from 48 hours to five days after a dose increase, and none of the guidance documents stated a pharmacokinetic basis for them. The Federal Aviation Administration halved its observation period after initiation within one year; no authority addressed reinitiation after missed doses, and only one explicitly covered cabin crew. A phase-based protocol is proposed in which stand-down periods follow the half-life of each agent, with four weeks after initiation and seven days after each dose increase for the weekly agents, and two weeks and three days, respectively, for orforglipron. A multi-pilot limitation would apply until the maintenance dose reaches steady state, followed by periodic review of weight, heart rate, blood pressure, and symptoms. Specific rules address missed doses, switches between agents or formulations, and cabin crew. A harmonized approach grounded in pharmacology may protect flight safety while allowing aircrew to benefit from treatment and to disclose it.
Authors
- Piercarlo Minoretti (ORCID: https://orcid.org/0000-0002-6512-611X)
Publication Details
- Journal
- Cureus
- Published
- 2026-11-17
- DOI
- https://doi.org/10.7759/cureus.119808
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00